LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development.Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 23, 2022 | Series C | $175M | 1 | — | — | Detail |
| Jan 7, 2021 | Series B | $50M | 1 | — | — | Detail |
| Sep 18, 2017 | Series A | $70M | 2 | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series C |
Merck
|
— | Series A |